Gufic Biosciences Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Gufic Biosciences Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $12.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Gufic Biosciences Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $12.6M Trade | TransData Nexus

Gufic Biosciences Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $12.6M Total Trade · DGFT Verified

Gufic Biosciences Limited is an Indian pharmaceutical exporter with a total trade value of $12.6M across 5 products in 4 therapeutic categories. Based on 355 verified export shipments from Indian Customs (DGFT) records, Gufic Biosciences Limited is the #1 Indian exporter in 1 product including Teicoplanin. Top exports include Vancomycin ($5.2M), Teicoplanin ($4.3M), Strip ($1.9M).

Gufic Biosciences Limited — Export Portfolio & Destination Treemap

Gufic Biosciences Limited pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Gufic Biosciences Limited? — Company Overview & Market Position

Gufic Biosciences Limited, established in 1970, is a prominent Indian pharmaceutical company specializing in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic formulations, and lyophilized injectable products. Incorporated as a public company on December 23, 1984, it is headquartered in Mumbai, Maharashtra, India. The company is listed on both the National Stock Exchange (NSE) under the ticker symbol GUFICBIO and the Bombay Stock Exchange (BSE) with the code 509079.

Gufic Biosciences operates with a promoter holding of 92.83% and a public holding of 4.10%, reflecting a strong promoter commitment. The company's Corporate Identification Number (CIN) is L24100MH1984PLC033519. As of the latest available data, Gufic Biosciences employs approximately 1,484 individuals. The company's official website is gufic.com.

What Does Gufic Biosciences Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Vancomycin$5.2M 2Teicoplanin

Product Portfolio — Top 5 by Export Value

Gufic Biosciences Limited exports 5 pharmaceutical products across 4 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vancomycin	Antibiotics	$5.2M	165	5.6%	7
2	Teicoplanin	Advanced Antibiotics	$4.3M	87	69.2%	1
3	Strip	Medical Devices & Diagnostics	$1.9M	72	1.0%	8
4	Meropenem	Advanced Antibiotics	$750.0K	15	0.3%	4
5	Amphotericin	Antifungals	$422.5K	16	0.5%	9

Gufic Biosciences Limited exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $12.6M. The company is the #1 Indian exporter in 1 product: Teicoplanin. The top category is Antibiotics (41.0% of portfolio), followed by Advanced Antibiotics (40.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Gufic Biosciences Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Gufic Biosciences operates multiple manufacturing facilities across India, specializing in the production of lyophilized injections, active pharmaceutical ingredients (APIs), and herbal formulations. The company boasts a fully automated lyophilization plant, which is among the largest in India, enabling the production of a diverse range of products, including antibiotics, antifungals, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors.

Additionally, Gufic Biosciences has WHO-GMP compliant manufacturing plants for injectables and herbal products, as well as an API manufacturing plant catering to regulated markets. These facilities underscore the company's commitment to quality and regulatory compliance in its manufacturing processes.

3Key Leadership

The leadership team at Gufic Biosciences Limited is headed by:

Jayesh Pannalal Choksi: Chairman and Managing Director
Pranav Jayesh Choksi: Chief Executive Officer and Whole-Time Director
Pankaj Jayakumar Gandhi: Whole-Time Director
Devkinandan B. Roonghta: Chief Financial Officer
Nagesh Yarrabathina: Chief Operating Officer
Avik Das: Investor Relations Officer
Ami Naresh Shah: Senior Manager of Legal, Company Secretary, and Compliance Officer
Pinak Padhya: Associate Vice President - Sales and Marketing
Sunil Desai: Head of Human Resource Department
Ashok Laxman Dev: President of Operations

This team brings a wealth of experience and expertise to the company's strategic and operational initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Gufic Biosciences Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Gufic Biosciences Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has filed multiple Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA), facilitating the marketing of its products in the U.S. In Europe, Gufic has registered numerous Active Pharmaceutical Ingredients (APIs) and holds certifications from the European Medicines Agency (EMA), ensuring compliance with stringent European standards.

In the United Kingdom, Gufic's products are authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), reflecting the company's adherence to UK regulatory requirements. The company also holds certifications from the Therapeutic Goods Administration (TGA) in Australia and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, demonstrating its commitment to meeting international quality and safety standards.

2Emerging Markets

Gufic Biosciences Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to World Health Organization (WHO) Good Manufacturing Practices (GMP) and prequalification processes has been instrumental in facilitating market access in these regions. By obtaining WHO prequalification, Gufic ensures that its products meet international quality standards, thereby enhancing their acceptance in these emerging markets.

Gufic Biosciences Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Gufic Biosciences Limited has registered multiple facilities with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has filed several Abbreviated New Drug Applications (ANDAs), facilitating the marketing of its generic formulations in the U.S. market. Additionally, Gufic has submitted numerous Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, and there are no records of Form 483 observations, warning letters, or import alerts, indicating a strong compliance history.

2WHO & EU GMP

Gufic Biosciences Limited's manufacturing facilities are compliant with World Health Organization (WHO) Good Manufacturing Practices (GMP), ensuring that its products meet international quality standards. The company holds EU GMP certificates, demonstrating its adherence to European manufacturing standards. These certifications are crucial for accessing and maintaining a presence in regulated markets worldwide.

3CDSCO & Indian Regulatory

Gufic Biosciences Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Gufic Biosciences Limited operates in a competitive landscape with several key players in the pharmaceutical industry. In the lyophilized injectable segment, the company faces competition from both domestic and international manufacturers. While specific market share data is not available, Gufic's focus on specialized medicinal segments and its commitment to quality and innovation provide a competitive edge. The company's diversified product portfolio, including APIs, generic formulations, and herbal products, further strengthens its position in the market.

2Key Differentiators

Gufic Biosciences Limited's key differentiators include its specialization in lyophilized products, which are critical for certain medications requiring stability and efficacy. The company's fully automated lyophilization plant enhances production efficiency and product quality. Additionally, Gufic's strong emphasis on research and development drives innovation, enabling the company to introduce new products and improve existing formulations. The company's adherence to international quality standards, as evidenced by its WHO-GMP and EU-GMP certifications, further distinguishes it in the global market.

3Strategic Position

Frequently Asked Questions — Gufic Biosciences Limited

How many pharmaceutical products does Gufic Biosciences Limited export from India?

Gufic Biosciences Limited exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Vancomycin ($5.2M), Teicoplanin ($4.3M), Strip ($1.9M), Meropenem ($750.0K), Amphotericin ($422.5K). Total export value is $12.6M.

What is Gufic Biosciences Limited's total pharmaceutical export value?

Gufic Biosciences Limited's total pharmaceutical export value is $12.6M, based on 355 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Gufic Biosciences Limited the #1 Indian exporter?

Gufic Biosciences Limited is the #1 Indian exporter in 1 products: Teicoplanin (69.2% market share).

What therapeutic categories does Gufic Biosciences Limited cover?

Gufic Biosciences Limited exports across 4 therapeutic categories. The largest are Antibiotics (41.0%, 1 products), Advanced Antibiotics (40.5%, 2 products), Medical Devices & Diagnostics (15.1%, 1 products).

Get Full Gufic Biosciences Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.